Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalrestat in pediatric PMM2-CDG
NCT04925960Phase 3Terminated
- Sponsor
- Maggie's Pearl
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epalrestat in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), sponsored by Maggie's Pearl. Started Nov 2022; status: terminated.
02
Drugs
epalrestat
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on NCT04925960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925960.